Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients
Status:
Completed
Trial end date:
2021-05-14
Target enrollment:
Participant gender:
Summary
The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients
with treatment dose LMWH leads to better thromboembolic-free outcomes and associated
complications during hospitalization than prophylaxis with institutional standard of care
with prophylactic to intermediate-doses of UFH or LMWH